Eugia Pharma Receives USFDA Approval for Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL (5 mg/mL), and 125 mg/25 mL (5 mg/mL), Single-Dose Vials

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL (5 mg/mL), and 125 mg/25 mL (5 mg/mL), Single-Dose Vials.

Indications for this product include:

• Atrial Fibrillation or Atrial Flutter
• Paroxysmal Supraventricular Tachycardia

Refer to package insert for full prescribing information.